371 related articles for article (PubMed ID: 8823330)
21. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.
Repetto L; Biganzoli L; Koehne CH; Luebbe AS; Soubeyran P; Tjan-Heijnen VC; Aapro MS
Eur J Cancer; 2003 Nov; 39(16):2264-72. PubMed ID: 14556916
[TBL] [Abstract][Full Text] [Related]
22. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Link H; Nietsch J; Kerkmann M; Ortner P;
Support Care Cancer; 2016 Jan; 24(1):367-376. PubMed ID: 26081593
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
24. A Survey of Oncologists' Perceptions and Opinions Regarding the Use of Granulocyte Colony-Stimulating Factors.
Hawkins A; Murphy A; McNamara M; Gawade PL; Belani R; Kelsh MA
J Cancer Educ; 2020 Feb; 35(1):178-186. PubMed ID: 31656028
[TBL] [Abstract][Full Text] [Related]
25. [G-CSF in oncology].
Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
[TBL] [Abstract][Full Text] [Related]
26. Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.
Alvarez Secord A; Bae-Jump V; Havrilesky LJ; Calingaert B; Clarke-Pearson DL; Soper JT; Gehrig PA
Int J Gynecol Cancer; 2009 Apr; 19(3):447-54. PubMed ID: 19407573
[TBL] [Abstract][Full Text] [Related]
27. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
28. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
Thomas X; Boiron JM; Huguet F; Reman O; Sutton L; Turlure P; Garban F; Gardin C; Espinouse D; Boulat O; Lhéritier V; Fiere D;
Hematol J; 2004; 5(5):384-94. PubMed ID: 15448664
[TBL] [Abstract][Full Text] [Related]
31. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
[TBL] [Abstract][Full Text] [Related]
32. Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2018 Aug; 34(8):1351-1360. PubMed ID: 28722536
[TBL] [Abstract][Full Text] [Related]
33. Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey.
Falandry C; Krakowski I; Curé H; Carola E; Soubeyran P; Guérin O; Freyer G
Anticancer Res; 2014 Sep; 34(9):5007-15. PubMed ID: 25202084
[TBL] [Abstract][Full Text] [Related]
34. G-CSF as prophylaxis of febrile neutropenia in SCLC.
Adams JR; Lyman GH; Djubegovic B; Feinglass J; Bennett CL
Expert Opin Pharmacother; 2002 Sep; 3(9):1273-81. PubMed ID: 12186620
[TBL] [Abstract][Full Text] [Related]
35. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review.
Bohlius J; Reiser M; Schwarzer G; Engert A
Br J Haematol; 2003 Aug; 122(3):413-23. PubMed ID: 12877668
[TBL] [Abstract][Full Text] [Related]
36. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia.
Ohno R
Leuk Res; 1998 Dec; 22(12):1143-54. PubMed ID: 9922078
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic management in oncology practice. Part 1. Myeloid growth factors.
Glaspy JA
Oncology (Williston Park); 2003 Nov; 17(11):1593-603. PubMed ID: 14682110
[TBL] [Abstract][Full Text] [Related]
38. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
[TBL] [Abstract][Full Text] [Related]
40. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
